Alzheimer’s disease has long been defined by its devastating impact on memory, cognition, and personality—a progressive decline centered firmly within the gray matter of the brain. However, groundbreaking new research from the University of Central Florida (UCF) suggests that the disease’s reach may be far more extensive than previously understood, manifesting in a surprising location: the peripheral nervous system.

Scientists at UCF have discovered that genetic mutations associated with familial Alzheimer’s disease can directly interfere with the nerves that control muscle movement. Crucially, this disruption occurs independently of the brain or spinal cord. This discovery, published in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, offers a compelling explanation for why many patients experience physical symptoms—such as gait changes, balance issues, and coordination loss—years before the hallmarks of cognitive decline emerge.

Challenging the Brain-Centric Model

For decades, the medical community has focused almost exclusively on the brain when studying Alzheimer’s, viewing physical decline as a downstream effect of neural degradation. While patients have frequently reported movement difficulties early in the disease progression, these issues were often dismissed as secondary consequences of brain damage.

The research team, led by James Hickman, a professor at UCF’s Nanoscience Technology Center, and Research Professor Xiufang "Nadine" Guo, sought to challenge this assumption. Working in collaboration with the healthcare technology company Hesperos, the team utilized advanced laboratory models to isolate the neuromuscular system. By doing so, they aimed to determine if the peripheral nervous system—the network of nerves residing outside the brain and spinal cord that facilitates movement—could be a primary site of pathology.

"Motor deficits may be an earlier indication [of Alzheimer’s]," says Guo. "If we can detect those changes and intervene earlier, that could help delay the onset of central nervous system symptoms."

The implications for clinical practice are profound. If movement disorders are indeed an early warning sign, they could provide physicians with a vital window for intervention. Furthermore, the study suggests that current therapeutic approaches, which are almost entirely focused on targeting amyloid plaques or tau tangles within the brain, may be inadvertently overlooking systemic damage that contributes to patient disability.

A New Window into Familial Alzheimer’s

To conduct this study, the team focused on familial Alzheimer’s disease. This is a rare, inherited form of the condition that typically presents earlier in life, often affecting individuals between the ages of 40 and 65. By isolating the genetic components of this specific form of the disease, the researchers were able to observe the direct impact of these mutations on motor neurons—the specialized nerve cells that transmit electrical signals from the nervous system to muscles, dictating when to contract and move.

In a laboratory environment devoid of any brain or spinal cord tissue, the researchers observed that motor neurons carrying Alzheimer’s-linked mutations disrupted the vital communication link between nerves and muscles. This finding is the first of its kind, establishing that peripheral nervous system deficits can arise directly from these specific genetic triggers rather than merely reflecting a degradation of the central nervous system.

"This is the first time it’s been demonstrated that deficits in the peripheral nervous system can arise directly from these mutations," says Hickman. "It means drugs that target the brain may not fix problems in the rest of the body."

The peripheral nervous system acts as the body’s communication highway, carrying signals that control everything from reflex actions to complex, coordinated movements. By demonstrating that Alzheimer’s mutations can cause "traffic jams" on this highway before the brain itself is significantly compromised, the study suggests that the disease may be a systemic process rather than a purely neurological one.

Innovative "Human-on-a-Chip" Technology

The ability to make such a discovery was made possible by an innovative laboratory platform known as "human-on-a-chip" technology. Developed through Hesperos, a company co-founded by Hickman, these miniature systems allow researchers to bring different types of human cells together in a controlled, highly precise environment.

Unlike traditional in vitro studies that rely on isolated cell cultures, or animal models that often fail to accurately mimic human disease progression, these chip-based systems recreate functional human biological interactions. For this study, the researchers engineered a miniature neuromuscular junction—the exact biological interface where a motor neuron meets a muscle cell.

By populating this model with healthy human muscle cells and motor neurons derived from stem cells carrying familial Alzheimer’s mutations, the team could observe the breakdown of communication in real-time. The stem cell technology was instrumental, as it allowed the researchers to replicate the specific genetic profile of the disease in a laboratory setting, providing a reliable proxy for how the disease might manifest in a human patient.

The Mechanics of Movement and Decline

Every voluntary movement, from the steady gait required for walking to the delicate coordination needed to hold a pen, relies on the seamless functioning of the neuromuscular junction. An electrical signal travels down the motor neuron, triggering a chemical exchange that prompts the muscle to contract. If this link is impaired, the result is muscle weakness, fatigue, and a loss of physical stability.

To evaluate the extent of the damage caused by the Alzheimer’s mutations, the research team performed rigorous functional testing. They measured the consistency of nerve-to-muscle signals and tracked how long the muscle cells could maintain contractions before showing signs of fatigue. These metrics served as a laboratory equivalent to the physical examinations physicians perform in clinics—such as the classic knee-jerk reflex test.

"You can’t move unless the motor circuit works," says Hickman. "When a doctor taps your knee to check your reflex, they’re testing that exact connection."

While the results are compelling, the researchers remain cautious about generalizing these findings to the broader population. The study specifically addressed familial Alzheimer’s; further investigation is required to determine how these peripheral mechanisms correlate with the more common, late-onset form of the disease. However, the evidence provides a strong foundation for a new line of inquiry into the early, non-cognitive markers of the condition.

The Future of Alzheimer’s Diagnostics and Treatment

The potential for this research to reshape the diagnostic landscape is significant. If future longitudinal studies confirm that motor dysfunction is a reliable precursor to cognitive impairment, it could lead to the development of early-screening protocols that focus on gait analysis and neuromuscular testing. Detecting these issues early could allow for earlier clinical monitoring, lifestyle modifications, or the administration of future therapies designed to protect both motor and cognitive health.

Guo emphasizes that the benefits of protecting motor function extend beyond the physical realm. There is a well-established link between physical activity and cognitive well-being; by maintaining the body’s ability to stay active, patients may be better equipped to support their own brain health for longer.

Furthermore, the "human-on-a-chip" platform offers a roadmap for the future of pharmaceutical development. By allowing researchers to see how a drug affects the interaction between different tissue types, scientists can better identify potential side effects or determine if a therapy is effectively reaching both the brain and the peripheral nerves.

For Professor Hickman, this discovery is the culmination of thirty years of dedicated research into creating more authentic laboratory models of human disease. By moving away from oversimplified experimental setups and toward systems that mirror the complexity of human physiology, the team has provided a new perspective on one of the most challenging medical mysteries of our time.

"These systems let us study disease in a way that’s closer to what actually happens in the human body, and that’s what we need to develop better treatments," Hickman says. As the research progresses, the hope is that this new understanding of the peripheral nervous system’s role in Alzheimer’s will lead to more comprehensive, patient-centered care that addresses the disease in all its complexity, both inside and outside the brain.